Inhibition of Human Cytochrome P450 Enzymes by Allergen Removed Rhus verniciflua Stoke Standardized Extract and Constituents

Abstract

Objective. Potential interactions between herbal extracts and the cytochrome P450 (CYP) system lead to serious adverse events or decreased drug efficacy. Rhus verniciflua stoke (RVS) and its constituents have been reported to have various pharmacological properties. We evaluated the inhibitory potential of RVS and its constituents on the major CYP isoforms. Methods. The effects of allergen removed RVS (aRVS) standardized extract and major components, fustin and fisetin isolated from aRVS, were evaluated on CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 isoenzyme activity by a luminescent CYP recombinant human enzyme assay. Results. The aRVS extract showed relative potent inhibitory effects on the CYP2C9 (IC50, <0.001 μg/mL), CYP2C19 (IC50, 9.68 μg/mL), and CYP1A2 (IC50, 10.0 μg/mL). However, it showed weak inhibition on CYP3A4 and CYP2D6. Fustin showed moderate inhibitory effects on the CYP2C19 (IC50, 64.3 μg/mL) and weak inhibition of the other CYP isoforms similar to aRVS. Fisetin showed potent inhibitory effects on CYP2C9, CYP2C19, and CYP1A2. Fisetin showed moderate inhibition of CYP2D6 and weak inhibition of CYP3A4. Conclusions. These results indicate that aRVS, a clinically available herbal medicine, could contribute to herb-drug interactions when orally coadministered with drugs metabolized by CYP2C9, CYP2C19, and CYP1A2.

The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways

“…Additionally, herbal medicines, which are orally administered, could affect bioavailability of co-administered drugs. In addition, several herbs can give rise to the potential of harmful interactions with targeted agents [67,68]. In our study, we aimed to test the inhibitory effects of fisetin on CYP3A4 involved in the hepatic metabolism of most drugs.…”

Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro

“…Due to the fact that CYP3A4 metabolizes more than 50 % of the clinically prescribed drugs and represents the major metabolic enzyme in the human liver (40 %) and intestinal mucosa (80 %), CYP3A4 could contribute significantly to the metabolism of herbal drugs because most of the herbal drugs including EEDS are orally administered and metabolized primarily by the drug metabolizing enzymes in the liver and intestinal mucosa [ 6 , 31 , 32 ]. If EEDS is developed as a new anticancer herbal drug, EEDS could possibly be taken together with other conventional anticancer drugs.…”

Nanocarriers for natural polyphenol senotherapeutics

“…Fisetin acts as a competitive inhibitor against CYP2C9, with a ki value of less than 2.2 μM, implying its binding to the substrate‐binding site. Additionally, it exhibits a strong inhibitory effect on CYP2C19 and CYP1A2, and a weaker inhibition on CYP3A4 and CYP2D6 (Jung & Lee, 2014 ; Si et al., 2009 ). This can result in drug interactions when co‐administering flavonoids with other drugs, potentially causing increased toxicity and reduced therapeutic effect (Tang & Stearns, 2001 ).…”